ABSTRACT
OBJECTIVES: To acquire current information on sleep habits, disturbances and treatment options in the adult population of Austria and compare results with previously collected data. MATERIALS AND METHODS: A representative sample of the Austrian population (women: n = 522, men: n = 478). RESULTS: Seventy-five percent reported daily sleep-duration between 6 and 8 h. In 76%, sleep latency was <30 min, 15% described difficulties in sleep maintenance. Longer sleep on weekends was prevalent in 54%, 23% took a nap. Concerning sleep environment, 31% reported sleeping alone; the rest had a constant or occasional bed partner. Sleep disturbances such as sleep disruption or prolonged sleep latency were reported by 18%. Predominant symptoms included snoring/apneas (22%), nightmares (22%) and restless legs (21%). Daytime tiredness was reported by 17% and sleepiness by 20%. Twenty-four percent did not take treatment. Only 7% asked for medical help: 96% consulted their physician; 47% tried to change their way of living. Sleep promoting drugs were taken by 7%. Sleep improving measures were: sleep promoters (45%), general measures (20%), consultation of general practitioner (20%), psychotherapy (6%), and technical tools (3%). Comparison with a dataset of 1993 revealed only a slight increase in short sleepers and a slight decrease in long sleepers. CONCLUSIONS: Subjectively reported sleep disorders proved to be relatively stable between 1993 and 2007.
Subject(s)
Habits , Sleep Wake Disorders , Sleep/physiology , Adolescent , Adult , Austria/epidemiology , Female , Humans , Male , Middle Aged , Sleep Wake Disorders/epidemiology , Sleep Wake Disorders/psychology , Sleep Wake Disorders/therapy , Young AdultABSTRACT
The authors present a group of nine patients suffering from mesenteric venous thrombosis, which were treated in three hospitals with participation of the first author. Basic principles of diagnostic and therapeutic procedure are summarized and a shift in the treatment strategy over the last 10 years is pointed out. The patient after a very radical intestinal resection may expect to survive and entertain an acceptable quality of life, provided the surgery is followed by an extensive team care in the post-operation period, later accompanied by the care of specialists in modern ways of nutrition.
Subject(s)
Mesenteric Vascular Occlusion/surgery , Venous Thrombosis/surgery , Aged , Female , Gangrene/etiology , Gangrene/surgery , Humans , Intestines/pathology , Intestines/surgery , Male , Mesenteric Vascular Occlusion/complications , Mesenteric Veins , Middle Aged , Venous Thrombosis/complicationsABSTRACT
PURPOSE: To evaluate the effect of mitomycin C to an accelerated hyperfractionated radiation therapy. The aim was to test a very short schedule with/without mitomycin C (MMC) with conventional fractionation in histologically verified squamous cell carcinoma of the head and neck region. METHODS AND MATERIALS: From October 1990 to December 1996, 188 patients entered the trial. Tumors originated in the oral cavity in 54, oropharynx in 82, larynx in 20, and hypopharynx in 32 cases, respectively. Patients' stages were predominantly T3 and T4 (158/188, 84%) and most patients had lymph node metastases (144/188, 77%) at diagnosis. Only 22 patients were female, 166 were male, the median age of patients was 57 years (range 34 to 76 years). Patients were randomized to one of the following three treatment options: conventional fractionation (CF) consisting of 70 Gy in 35 fractions over 7 weeks (65 patients) or continuous hyperfractionated accelerated radiation therapy (V-CHART; 62 patients) or continuous hyperfractionated accelerated radiation therapy with 20 mg/sqm MMC on day 5 (V-CHART + MMC; 61 patients). By the accelerated regimens, the total dose of 55.3 Gy was delivered within 17 consecutive days, by 33 fractions. On day 1, a single dose of 2.5 Gy was given, from day 2 to 17 a dose of 1.65 Gy was delivered twice: the interfraction interval was 6 hours or more. RESULTS: Mucositis was very intense after accelerated therapy, most patients experiencing a grade III/IV reaction. The mucosal reaction did not differ whether MMC was administered or not. Patients treated by accelerated fractionation experienced a confluent mucosal reaction 12-14 days following start of therapy and recovered (no reaction) within 6 weeks. The skin reaction was not considered different in the three treatment groups. Those patients treated with additional chemotherapy experienced a grade III/IV hematologic toxicity in 12/61 patients. Initial complete response (CR) was recorded in 43% following CF, 58% after V-CHART, and 67% after V-CHART + MMC, respectively (p < 0.05). Actuarial survival (Kaplan-Meier) was significantly improved in the combined treated patients. Local tumor control was 28%, 32%, and 56% following CF, V-CHART, and V-CHART + MMC, respectively (p < 0.05). CONCLUSION: We conclude that our continuous hyperfractionated accelerated radiation therapy regimen is equal to conventional fractionation, suggesting that by shortening the overall treatment time from 7 weeks to 17 days a reduction in dose from 70 Gy to 55.3 Gy is possible, with maintenance of local tumor control rates. The administration of MMC to the accelerated regimen is tolerable and improves the outcome for patients significantly.
Subject(s)
Antibiotics, Antineoplastic/therapeutic use , Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/radiotherapy , Mitomycin/therapeutic use , Adult , Aged , Combined Modality Therapy , Dose Fractionation, Radiation , Female , Humans , Male , Middle Aged , Radiotherapy Dosage , Survival AnalysisABSTRACT
From October 1990 to March 1994, 90 patients entered a prospectively randomised trial in head and neck cancer. All patients had verified squamous cell carcinoma and were referred for primary radiation therapy. Tumours originated in the oral cavity in 25, oropharynx in 37, larynx in 15 and hypopharynx in 13 cases. Patients' stages were predominantely T3 and T4 (71/90) and had lymph node metastases (60/90). Seventy-nine male patients and 11 female patients, with a median age of 57 years (range 37-76 years) were treated. Patients were randomised to one of three treatment options: conventional fractionation (CF) consisting of 70 Gy in 35 fractions over 7 weeks or continuous hyperfractionated accelerated radiation therapy (Vienna-CHART) or Vienna-CHART with administration of a single dose of mitomycin C on day 5 of treatment (V-CHART + MMC). By the accelerated regimen a total dose of 55.3 Gy was given in 33 fractions within 17 consecutive days. Acute mucositis was the main toxicity recorded in those patients treated by accelerated fractionation, although the overall duration of mucosal reaction did not differ in the three treatment groups. There was no influence on local toxicity if MMC was added to radiation therapy or not. Those patients treated with additional MMC experienced a grade III/IV haematological toxicity in 4/28 cases. Complete remission (CR) was recorded in 48% following CF, 79% after Vienna-CHART (P < 0.05) and 71% after Vienna-CHART + MMC. The overall local failure rates were 73%, 59% and 42% (P = NS) for patients treated by CF, Vienna-CHART and Vienna-CHART + MMC respectively.
Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/radiotherapy , Adult , Aged , Female , Humans , Male , Middle Aged , Mitomycin/adverse effects , Mitomycin/therapeutic use , Prospective Studies , Radiotherapy DosageABSTRACT
From May 1990 to May 1991, 23 patients with advanced, inoperable squamous cell cancers, clinically staged as III or IV, were treated by unconventional fractionation radiotherapy. Treatment consisted of a continuous hyperfractionated accelerated radiotherapy, delivering a total dose of 55.3 Gy within 17 consecutive days. In ten patients radiation therapy was combined with chemotherapy; 20 mg mitomycin C/m2, administered by intravenous bolus injection on day 5 of treatment. Apart from a confluent mucositis, treatment tolerance was good. Haematological toxicity from mitomycin C was minor and did not require any specific therapy. The mucosal reaction lasted six weeks (median duration) and was not thought to be increased by additional chemotherapy. In twelve of 23 patients a complete remission of the primary tumour was seen, in patients with lymph node metastases there was a complete response in 14 out of 20 patients. After a median follow-up of 18 months, ten of 23 patients have survived (8/23 without evidence of disease). Eleven patients have died due to local tumour progression and one patient died with distant metastases, being without evidence of local tumour. The advantage of this unconventional fractionation, which takes the described short potential tumour doubling time for head and neck cancers into account, is discussed.
Subject(s)
Carcinoma, Squamous Cell/radiotherapy , Head and Neck Neoplasms/radiotherapy , Adult , Aged , Aged, 80 and over , Carcinoma, Squamous Cell/mortality , Combined Modality Therapy , Female , Head and Neck Neoplasms/mortality , Humans , Lymphatic Metastasis , Male , Middle Aged , Mitomycins/administration & dosage , Mitomycins/adverse effects , Pilot Projects , Radiation Tolerance , Radiotherapy Dosage , Radiotherapy, Computer-Assisted , Remission Induction , Time FactorsABSTRACT
Capillary electrophoresis (CE) separations are reported for sulfonamides and benzodiazepines in an uncoated fused-silica capillary. The capillary column exit was connected to a liquid junction-ion spray interface combination coupled to an atmospheric pressure ionization (API) triple quadrupole mass spectrometric (MS) system. On-line UV detection occurred 20 cm from the inlet of the capillary and with the API mass spectrometer (CE-API-MS) after the entire length of the capillary (100 cm). The separations were made using volatile buffers composed of ammonium acetate (15-20 mM) with 15-20% of methanol to facilitate ionization under electrospray conditions. This study showed that the major metabolite of flurazepam in man, N-1-hydroxyethylflurazepam, could be detected and characterized in human urine by CE-UV-MS following the administration of a single oral dose of 30 mg of flurazepam dihydrochloride. The presence of additional flurazepam metabolites in human urine was observed by using the system, suggesting that a combination of UV with MS detection should be useful for metabolic studies. In addition to molecular weight determination of compounds, structural information may be obtained by utilizing online tandem mass spectrometry (CE-UV-MS-MS). This was demonstrated for sulfamethazine where the protonated molecule species was transmitted into the collision cell of the tandem triple quadrupole mass spectrometer. Collision-induced dissociation of the protonated sulfamethazine molecule yielded structural information characteristic of the sulfa drug following the on-column injection of 2 pmol of sulfamethazine.
Subject(s)
Benzodiazepines/urine , Electrophoresis/methods , Mass Spectrometry/methods , Sulfonamides/urine , Flurazepam/urine , HumansABSTRACT
In this retrospective study the value of sonography in the preoperative staging of malignant tumours of the tonsils was evaluated in 36 patients. According to our results sonography is indicated in small tumours. In greater tumours, especially if bone destruction could be expected, MR or CT should be performed additionally to sonography. Good results were achieved in assessing the infiltration of the tongue with or without crossing the midline (accuracy 92 to 97%) and the detection of cervical lymph node metastasis (accuracy 94%).
Subject(s)
Carcinoma, Squamous Cell/diagnosis , Lymphoma, Non-Hodgkin/diagnosis , Tonsillar Neoplasms/diagnosis , Ultrasonography , Adult , Aged , Carcinoma, Squamous Cell/pathology , Female , Humans , Lymphatic Metastasis , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Neoplasm Invasiveness , Retrospective Studies , Tongue Neoplasms/diagnosis , Tongue Neoplasms/pathology , Tongue Neoplasms/secondary , Tonsillar Neoplasms/pathologyABSTRACT
Endoscopy permits visualization of the endolaryngeal spread of laryngeal tumors, yet the depth of tumor infiltration often remains unclear. The authors used high-resolution sonography in 37 patients with advanced laryngeal cancer to assess the tumors and the cervical lymph nodes. Sonographic findings were compared to operative and histologic reports. Sonography demonstrated histologically confirmed infiltration into the thyroid (n = 8) and cricoid cartilages (n = 1), preepiglottic space (n = 12), base of the tongue (n = 4), hypopharynx (n = 8), subglottic space (n = 3), and thyroid gland (n = 2). Except for the retrolaryngeal portion of the tumor, sonography was valuable in assessing extralaryngeal spread of advanced cancers. It enabled detection of subclinical lymph node metastases in four patients. Furthermore, invasion of the wall of the carotid artery was found in two patients. For evaluating the endolaryngeal and hypopharyngeal portions of the tumor, endoscopy remains mandatory.
Subject(s)
Laryngeal Neoplasms/diagnosis , Larynx/pathology , Ultrasonography , Female , Humans , Laryngeal Cartilages/pathology , Lymph Nodes/pathology , Lymphatic Metastasis , Male , Middle Aged , NeckABSTRACT
In the pre-operative staging of laryngeal carcinoma CT is of great clinical importance. We examined 20 cases of laryngeal cancer. In 20% of the cases, the CT evaluation indicated more advanced stages, thereby correcting the results of clinical staging. In 65% of the cases, clinical staging showed the same results as CT. 3 glottis tumours (15% of the patients) could not be identified by CT.
Subject(s)
Laryngeal Neoplasms/pathology , Neoplasm Staging/methods , Tomography, X-Ray Computed , Adult , Aged , Aged, 80 and over , Female , Glottis/diagnostic imaging , Glottis/pathology , Humans , Hypopharyngeal Neoplasms/diagnostic imaging , Hypopharyngeal Neoplasms/pathology , Laryngeal Neoplasms/diagnostic imaging , Male , Middle AgedABSTRACT
In selected patients with advanced head and neck cancer interstitial radiotherapy with Ir-192 can be used as a palliative treatment. Using two cases as examples, we report on our experiences with 19 patients.
Subject(s)
Brachytherapy , Head and Neck Neoplasms/radiotherapy , Iridium Radioisotopes/therapeutic use , Neoplasm Recurrence, Local/radiotherapy , Palliative Care , Aged , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/therapy , Combined Modality Therapy , Follow-Up Studies , Head and Neck Neoplasms/therapy , Humans , Iridium Radioisotopes/administration & dosage , Male , Neoplasm Recurrence, Local/therapy , Tongue Neoplasms/radiotherapy , Tongue Neoplasms/therapyABSTRACT
In an effort to improve preoperative evaluation of tumors of the tongue, a prospective study on the value of ultrasound (US) for the staging of 50 surgically proven cancers of the tongue and floor of mouth was performed. Sonography was correlated with clinical staging and surgical outcome. Real-time high-frequency transducers and an echo-free silicone interface were used. The dorsal and middle thirds of the tongue were scanned from a submental access and the tip of the tongue directly. US accurately defined tumor sizes and locations in all cases. US staged cancers correctly in all cases but one. In contrast, clinical staging was correct in only 66% of cases. Surgically relevant details, such as crossing of the midline of the tongue or infiltration of the lateral pharyngeal wall, were detected with US. The major limitations of US include the nonvisualization of the epiglottis and retropharyngeal space as well as bone infiltration.
Subject(s)
Tongue Neoplasms/pathology , Ultrasonography , Female , Humans , Male , Mandible/anatomy & histology , Mouth Floor , Mouth Neoplasms/pathology , Neoplasm Invasiveness , Neoplasm Staging , Prospective Studies , Tongue/anatomy & histology , Tongue Neoplasms/diagnosis , Ultrasonography/methodsABSTRACT
Based on our three years experience with about 200 transcutaneous real-time sonographies of the tongue and the floor of mouth, an assessment of the determination of size and site of 38 pretherapeutically examined malignant tumours (35 squamous cell carcinomas) was made. The patients were examined in reclined position, the head retroflected. Curved array transducers of 5 or 7.5 MHz and a silicon elastomer block as interface turned out to be optimal. All tumours could be detected by sonography as hypoechoic, more or less homogeneous, ill-defined areas. Two thirds of the tumour ulcerations could be seen as hard hyperechoic reflexes within the hypoechoic areas. When comparing the maximal diameter of tumours of the 20 operated patients, we found an agreement (5 mm tolerance) of sonography with the surgical specimen in 14 of 20 tumours (70%), of sonography with the clinically estimated diameter in 10 of 20 tumours (50%), whereas the clinically estimated diameter was in agreement with the surgical specimen in only 8 of 20 tumours (40%). A peritumoral inflammatory infiltration can simulate a larger tumour size in sonography. The extent of tumours within the tongue, to the floor of mouth, the lateral pharyngeal wall and the preepiglottic space was documented correctly in most cases. In three cases a previously unknown spread across the midline was found sonographically. Including the sonographic findings in the TNM classification, 5 T1 tumours would have been staged as T2 and one T3 tumour as T4. Inflammatory diseases of the tongue can show the same sonomorphology as malignant tumours.
Subject(s)
Mouth Neoplasms/pathology , Tongue Neoplasms/pathology , Ultrasonography , Adult , Aged , Aged, 80 and over , Carcinoma/pathology , Carcinoma, Squamous Cell/pathology , Humans , Lymphoma, Non-Hodgkin/pathology , Middle Aged , Mouth Floor/pathology , Mouth Neoplasms/surgery , Tongue/pathology , Tongue Neoplasms/surgeryABSTRACT
In a retrospective analysis, 42 patients with malignant primary tumor of the parotid gland were evaluated considering survival, local recurrence and tolerance of treatment. All patients referred to radiotherapy were treated by electron beam (10-15 MeV) and followed for more than 5 years. Postoperative radiotherapy after radical operation, with no macroscopic disease, was performed in 18 patients, 7 of whom were treated by radical re-operation and radiation of a recurrent parotid neoplasm. In these groups, the local recurrence rate was 4/18 (22%) and 2/7 (29%), the 5-year survival rate was 9/18 (50%) and 5/7 (71%). In 17 patients, radiotherapy started with gross tumor left behind. This group showed a local recurrence rate of 10/17 (59%) and a 5-year survival of 7/17 (41%). Treatment was well tolerated with no major sequelae. Local tumor control and its impact on survival is discussed.
Subject(s)
Electrons , Parotid Neoplasms/radiotherapy , Radiotherapy, High-Energy , Adult , Aged , Female , Humans , Male , Middle Aged , Neoplasm Recurrence, Local/epidemiology , Neoplasm Recurrence, Local/mortality , Parotid Neoplasms/mortality , Particle Accelerators , Radiotherapy Dosage , Retrospective StudiesABSTRACT
Carcinomas of the paranasal sinuses are usually advanced when diagnosed and present a therapeutic challenge. During the period between February 1970 and June 1981 44 patients were treated. 22 received postoperative irradiation, seven in combination with chemotherapy. 18 patients were treated with radiation alone, eleven with concomitant chemotherapy. Four patients received preoperative irradiation, three in combination with chemotherapy. The three-year survival is 43% and the five-year survival 33%. For those 26 patients who were irradiated pre- or postoperatively with or without concomitant chemotherapy the five-year survival is 45%. We believe the patient will be afforded the greatest opportunity for cure with the combined efforts of the radiotherapist and the surgeon. The combination of chemotherapy and radiotherapy did not provide better results but increased acute and chronic toxicity of the therapy.
Subject(s)
Paranasal Sinus Neoplasms/radiotherapy , Adult , Aged , Carcinoma/drug therapy , Carcinoma/radiotherapy , Carcinoma/surgery , Carcinoma, Adenoid Cystic/drug therapy , Carcinoma, Adenoid Cystic/radiotherapy , Carcinoma, Adenoid Cystic/surgery , Carcinoma, Squamous Cell/drug therapy , Carcinoma, Squamous Cell/radiotherapy , Carcinoma, Squamous Cell/surgery , Combined Modality Therapy , Female , Humans , Male , Middle Aged , Paranasal Sinus Neoplasms/drug therapy , Paranasal Sinus Neoplasms/surgery , PrognosisABSTRACT
Frequently, correct evaluation of space-occupying lesions in the tongue is not possible with clinical methods only. In an attempt to assess the value of sonography in the detection of tongue lesions, we used submental sonography to examine 62 patients with suspicious palpatory findings upon physical examination of the tongue. Ultrasound detected 45 out of 47 tumours that were eventually confirmed either by surgery or by biopsy. Inadequate technique was the only factor that affected the detection rate. Sonography appears to be a reasonable guide in determining size and site of a tumour of the tongue. Thus, more precision in therapy planning may be achieved.
Subject(s)
Tongue Neoplasms/diagnosis , Ultrasonography , Aged , Carcinoma, Squamous Cell/diagnosis , Female , Humans , Male , Middle AgedABSTRACT
92 sonographic examinations performed in 62 patients were evaluated to determine the possible application of sonography in the diagnosis and follow-up of malignant tumours of the tongue. Squamous cell carcinomas were by far dominant and proved to be hypoechoic, mainly inhomogeneous and ill-defined masses. In most cases, they ranged between 2 and 4 cm. in diameter. In 50% of the lesions an infiltration of the pharynx wall was confirmed, and exulcerations were correctly detected by sonography in 75%. In preoperative determination of the size of the tumour, sonography correctly detected the size in 93% of the cases and was thus markedly superior to the clinical palpatory examination, which determined a mere 43% correctly. Sonography should be included in the pretherapeutic staging of tumours of the tongue to objectify the clinical findings. It is also adequate to document tumour behaviour during radiation.